Quest Diagnostics, Inc.’s filing revealed that its SVP, Clinical Solutions KUPPUSAMY KARTHIK unloaded Company’s shares for reported $0.25 million on Apr 29 ’24. In the deal valued at $140.00 per share,1,760 shares were sold. As a result of this transaction, KUPPUSAMY KARTHIK now holds 13,435 shares worth roughly $1.82 million.
Then, PREVOZNIK MICHAEL E sold 5,611 shares, generating $706,313 in total proceeds. Upon selling the shares at $125.88, the SVP & General Counsel now owns 38,478 shares.
Before that, Doherty Catherine T. sold 1,187 shares. Quest Diagnostics, Inc. shares valued at $149,420 were divested by the EVP, Regional Businesses at a price of $125.88 per share. As a result of the transaction, Doherty Catherine T. now holds 68,412 shares, worth roughly $9.28 million.
Leerink Partners initiated its Quest Diagnostics, Inc. [DGX] rating to a Market perform in a research note published on February 26, 2024; the price target was $135. A number of analysts have revised their coverage, including Jefferies’s analysts, who increased its forecast for the stock in early February from “a Hold” to “a Buy”. Barclays began covering DGX with “an Equal weight” recommendation on January 03, 2024. BofA Securities revised its rating on December 12, 2023. It rated DGX as “a Buy” which previously was an “a Neutral”.
Price Performance Review of DGX
On Monday, Quest Diagnostics, Inc. [NYSE:DGX] saw its stock fall -1.27% to $135.64. Over the last five days, the stock has lost -2.77%. Quest Diagnostics, Inc. shares have fallen nearly -1.62% since the year began. Nevertheless, the stocks have risen 0.17% over the past one year. While a 52-week high of $145.58 was reached on 01/02/24, a 52-week low of $119.59 was recorded on 02/01/24. SMA at 50 days reached $130.38, while 200 days put it at $131.08. A total of 0.75 million shares were traded, compared to the trading of 0.64 million shares in the previous session.
Levels Of Support And Resistance For DGX Stock
The 24-hour chart illustrates a support level at 134.76, which if violated will result in even more drops to 133.89. On the upside, there is a resistance level at 137.31. A further resistance level may holdings at 138.99. The Relative Strength Index (RSI) on the 14-day chart is 55.63, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.17, which suggests price will go up in the next trading period. Percent R suggests that price movement has been low at 40.02%. Stochastics %K at 64.75% indicates the stock is a holding.
The most recent change occurred on June 29, 2023 when Piper Sandler began covering the stock and recommended ‘”a Neutral”‘ rating.
